Sector
PharmaceuticalsOpen
₹327.05Prev. Close
₹331.25Turnover(Lac.)
₹13.25Day's High
₹339.75Day's Low
₹322.252 Week's High
₹417.8552 Week's Low
₹241Book Value
₹117.08Face Value
₹10Mkt Cap (₹ Cr.)
186.91P/E
20.16EPS
16.1Divi. Yield
1.3914 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
18 May 2024
12:00 AM
Dividend
Dividend Amount: 4.5
Record Date: 02 Aug, 2024
18 May 2024
12:00 AM
AGM
Announcement Date: 18 May, 2024
16 Jul 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 5.76 | 5.76 | 5.76 | 5.76 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 63 | 56.4 | 48.94 | 42.83 |
Net Worth | 68.76 | 62.16 | 54.7 | 48.59 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 69.39 | 57.45 | 59.47 | 41.01 |
yoy growth (%) | 20.78 | -3.4 | 45.02 | -6.1 |
Raw materials | -48.97 | -37.18 | -36.15 | -24.04 |
As % of sales | 70.57 | 64.71 | 60.78 | 58.62 |
Employee costs | -6.61 | -6.25 | -7.49 | -6.25 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 9.1 | 8.74 | 8.12 | 5.17 |
Depreciation | -0.63 | -0.78 | -0.96 | -0.75 |
Tax paid | -2.33 | -2.38 | -2.17 | -1.41 |
Working capital | -0.33 | 4.99 | 9.66 | 1.37 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 20.78 | -3.4 | 45.02 | -6.1 |
Op profit growth | 6.64 | -5.14 | 67.27 | 11.67 |
EBIT growth | 3.34 | 2.47 | 62.25 | 1.81 |
Net profit growth | 13.58 | 7.01 | 57.84 | 12.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.6 | 95.32 | 4,07,551.04 | 2,000.46 | 0.94 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,618.65 | 79.57 | 1,75,704.36 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,531.1 | 25.69 | 1,23,674.79 | 1,485.4 | 1.04 | 4,254.47 | 397.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,602.5 | 64.43 | 1,21,919.49 | 474 | 0.17 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,601.3 | 63.48 | 1,07,363.13 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson & Managing Director
Jayashree Nair
Joint Managing Director & CFO
S C Kachhara
Non Executive Director
Karthika Nair
Company Sec. & Compli. Officer
Nikita Phatak
Independent Director
Prabhakar Dalal
Independent Director
Mitul Patel
Independent Director
Suresh Chandra Kookada
Nair Baug,
Akurli Road Kandivli (E),
Maharashtra - 400101
Tel: 91-22-28871370/28870834
Website: http://www.bdhind.com
Email: comp.sec@bdhind.com
C-101 1st Floor,
247 Park Vikhroli W, Lal Bahadur Marg,
Mumbai - 400 083
Tel: -
Website: www.tsrdarashaw.com
Email: csg-unit@tsrdarashaw.com
Summary
Incorporated in 1990 as a private limited company, BDH Industries (BDHIL) was converted into a public limited company in 1994. It was established to take over a going concern, Bombay Drug House Pvt Lt...
Read More
Reports by BDH Industries Ltd
What is the BDH Industries Ltd share price today?
What is the Market Cap of BDH Industries Ltd?
What is the PE and PB ratio of BDH Industries Ltd?
What is the 52 Week High and Low of BDH Industries Ltd?
What is the CAGR of BDH Industries Ltd?
What is the shareholding pattern of BDH Industries Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.